03 October 2024
03 October 2024
Focus is turning to the development of peptide analogues of antibody-derived radiotherapeutics, according to Dr Dave Madge.
The initiative is expected to optimise processes, boost trial medicine capacity, and reduce both costs and environmental impact.
The Series B funds will expedite pipeline expansion and cover a clinical proof-of-concept study for TRIV-573.
The cash-saving measures come after interim analysis showed the company’s lead cancer drug only showed modest improvement in survival.
Exscientia detailed how its robotics lab in Oxfordshire, UK, is increasing productivity and efficiency in developing new molecules at ELRIG 2024.
The funds will support the development of LoQus23’s lead candidate, its MutSβ inhibitor, as it enters clinical development.
The move aligns with Gilead's strategy to ensure the availability of lenacapavir worldwide for PrEP.
Vevizye is used to treat moderate to severe DED in adults unresponsive to tear substitutes.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
